Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis.

Breast cancer (BC) continues to pose a significant burden on global cancer-related morbidity and mortality, primarily driven by metastasis. However, the combined influence of microRNAs (miRNAs) and intratumoral microbiota on BC metastasis remains largely unexplored. In this study, we aimed to elucidate the interplay between intratumoral microbiota composition, miRNA expression profiles, and their collective influence on metastasis development in BC patients by employing 16S rRNA sequencing and qPCR methodologies. Our findings revealed an increase in the expression of miR-149-5p, miR-20b-5p, and miR-342-5p in metastatic breast cancer (Met-BC) patients. The Met-BC patients exhibited heightened microbial richness and diversity, primarily attributed to diverse pathogenic bacteria. Taxonomic analysis identified several pathogenic and pro-inflammatory species enriched in Met-BC, contrasting with non-metastatic breast cancer (NonMet-BC) patients, which displayed an enrichment in potential probiotic and anti-inflammatory species. Notably, we identified and verified a baseline prognostic signature for metastasis in BC patients, with its clinical relevance further validated by its impact on overall survival. In conclusion, the observed disparities in miRNA expression and species-level bacterial abundance suggest their involvement in BC progression. The development of a prognostic signature holds promise for metastasis risk assessment, paving the way for personalized interventions and improved clinical outcomes in BC patients.

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

Multiple myeloma (MM) is a genetically heterogeneous disease and the management of relapses is one of the biggest clinical challenges. TP53 alterations are established high-risk markers and are included in the current disease staging criteria. KRAS is the most frequently mutated gene affecting around 20% of MM patients. Applying Clonal Competition Assays (CCA) by co-culturing color-labeled genetically modified cell models, we recently showed that mono- and biallelic alterations in TP53 transmit a fitness advantage to the cells. Here, we report a similar dynamic for two mutations in KRAS (G12A and A146T), providing a biological rationale for the high frequency of KRAS and TP53 alterations at MM relapse. Resistance mutations, on the other hand, did not endow MM cells with a general fitness advantage but rather presented a disadvantage compared to the wild-type. CUL4B KO and IKZF1 A152T transmit resistance against immunomodulatory agents, PSMB5 A20T to proteasome inhibition. However, MM cells harboring such lesions only outcompete the culture in the presence of the respective drug. To better prevent the selection of clones with the potential of inducing relapse, these results argue in favor of treatment-free breaks or a switch of the drug class given as maintenance therapy. In summary, the fitness benefit of TP53 and KRAS mutations was not treatment-related, unlike patient-derived drug resistance alterations that may only induce an advantage under treatment. CCAs are suitable models for the study of clonal evolution and competitive (dis)advantages conveyed by a specific genetic lesion of interest, and their dependence on external factors such as the treatment.

Fístula gastrocólica como causa infrecuente de diarrea persistente en un paciente portador de gastrostomía radiológica percutánea / Gastrocolic fistula as infrequent cause of chronic diarrhea in a patient with percutaneous radiological gastrostomy

Introducción: la fístula gastrocólica supone una complicación infrecuente pero potencialmente grave de las sondas de gastrostomía. La sospecha clínica ante una diarrea de origen incierto que comienza tras el recambio de la sonda es clave para la detección y el tratamiento precoces. Caso clínico: se presenta el caso de un paciente portador de gastrostomía radiológica percutánea (PRG) que comienza con diarrea persistente tras el primer recambio de la sonda y desnutrición grave secundaria. Tras el fracaso de las medidas terapéuticas iniciales se amplían los estudios, con hallazgo de esta complicación en la imagen de TC. Se suspende el uso de esta sonda con resolución de la diarrea y evolución nutricional favorable. Discusión: este caso pone de manifiesto la importancia de incluir la fístula gastrocólica en el diagnóstico diferencial de la diarrea persistente en un paciente portador de sonda de gastrostomía.(AU)

Introduction: gastrocolic fistula is an infrequent but severe complication of percutaneous gastrostomy. Clinical suspicion in the presence of chronic diarrhea of unknown etiology manifesting after percutaneous radiological gastrostomy (PRG) tube replacement is key to early detection and treatment. Case report: we report the case of a patient with PRG that began with chronic diarrhea after tube replacement and developed severe malnutrition. Initial treatment was not effective, studies were extended with the finding of this complication in a CT image. The use of this tube was discontinued with resolution of diarrhea and a favorable nutritional outcome. Discussion: this case report shows the importance of considering gastrocolic fistula in the differential diagnosis of persistent diarrhea in a patient with a gastrostomy tube.(AU)

[Gastrocolic fistula as infrequent cause of chronic diarrhea in a patient with percutaneous radiological gastrostomy]. / Fístula gastrocólica como causa infrecuente de diarrea persistente en un paciente portador de gastrostomía radiológica percutánea.

Introduction: Introduction: gastrocolic fistula is an infrequent but severe complication of percutaneous gastrostomy. Clinical suspicion in the presence of chronic diarrhea of unknown etiology manifesting after percutaneous radiological gastrostomy (PRG) tube replacement is key to early detection and treatment. Case report: we report the case of a patient with PRG that began with chronic diarrhea after tube replacement and developed severe malnutrition. Initial treatment was not effective, studies were extended with the finding of this complication in a CT image. The use of this tube was discontinued with resolution of diarrhea and a favorable nutritional outcome. Discussion: this case report shows the importance of considering gastrocolic fistula in the differential diagnosis of persistent diarrhea in a patient with a gastrostomy tube.

Introducción: Introducción: la fístula gastrocólica supone una complicación infrecuente pero potencialmente grave de las sondas de gastrostomía. La sospecha clínica ante una diarrea de origen incierto que comienza tras el recambio de la sonda es clave para la detección y el tratamiento precoces. Caso clínico: se presenta el caso de un paciente portador de gastrostomía radiológica percutánea (PRG) que comienza con diarrea persistente tras el primer recambio de la sonda y desnutrición grave secundaria. Tras el fracaso de las medidas terapéuticas iniciales se amplían los estudios, con hallazgo de esta complicación en la imagen de TC. Se suspende el uso de esta sonda con resolución de la diarrea y evolución nutricional favorable. Discusión: este caso pone de manifiesto la importancia de incluir la fístula gastrocólica en el diagnóstico diferencial de la diarrea persistente en un paciente portador de sonda de gastrostomía.

Anterior Scleral Thickness and Anterior Segment Biometrics Measured with Swept Source Ocular Coherence Tomography in High Myopic Eyes with and without Glaucoma: A Comparative Study.

Background: To assess the anterior scleral thickness (AST), Schlemm's canal diameter (SCD), trabecular meshwork diameter (TMD) and conjunctiva tenon capsule thickness (CTT) in high myopic (HM) subjects and HM subjects with glaucoma (HMG) compared to control eyes. Methods: One hundred and twenty eyes were included, and AST at 0, 1, 2 and 3 mm from the scleral spur, SCD, TMD and CTT were measured. Results: Mean age was 64.2 ± 11.0 years, and the temporal SCD and temporal TMD were significantly longer in the HMG subjects compared to the controls (380.0 ± 62 µm vs. 316.7 ± 72 µm, p = 0.001) and (637.6 ± 113 µm vs. 512.1 ± 97 µm, p = 0.000), respectively. There were no significant differences between the HM and HMG subjects in SCD and TMD (all p > 0.025). Compared to the HM subjects, the temporal AST0 (432.5 ± 79 µm vs. 532.8 ± 99 µm, p = 0.000), temporal AST1 (383.9 ± 64 µm vs. 460.5 ± 80 µm, p = 0.000), temporal AST2 (404.0 ± 68 µm vs. 464.0 ± 88 µm, p = 0.006) and temporal AST3 (403.0 ± 80 µm vs. 458.1 ± 91 µm, p = 0.014) were significantly thinner in the HMG group. No differences were found between the CTT in the three groups (all p > 0.025). Conclusions: Our data indicate a thinner AST in HMG subjects and no differences in SCD and TMD between HM and HMG subjects.

Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view.

Background: Acute kidney injury (AKI) in patients with multiple myeloma (MM) requiring renal replacement treatment (RRT) is associated with high morbidity and mortality. Early reduction of serum free light chains (FLC) using both targeted therapy against MM and intensive hemodialysis (IHD) may improve renal outcomes. We evaluated the effectiveness of two different RRT techniques on renal recovery in an MM patient population: standard dialysis procedure vs IHD with either polymethylmethacrylate (PMMA) or hemodiafiltration with endogenous reinfusion (HFR). Methods: This was a multicentric retrospective study with severe AKI related to MM, between 2011 and 2018. Twenty-five consecutive patients with AKI secondary to MM requiring RRT were included. Patients that underwent IHD received six dialysis sessions per week during the first 14 days (PMMA vs HFR). All patients were diagnosed with de novo MM or first relapsed MM. Primary outcome was renal recovery defined as dialysis-free at 6 months follow-up. Results: A total of 25 patients were included. Seventeen patients received IHD and eight standard dialysis. All patients were treated with targeted therapy, 84% bortezomib-based. Of the 25 patients included, 14 (56%) became dialysis independent. We observed a higher proportion of patients who received IHD in the group who recovered kidney function compared with those who remained in HD (92.9% vs 36.4%, P = .007). In our study, the use of IHD to remove FLC had a statistically significant association with renal recovery compared with the standard dialysis group (P = .024). Conclusion: Early reduction of FLC with IHD as an adjuvant treatment along with MM-targeted therapy may exert a positive impact on renal recovery.

Características clínicas y forma de presentación en pacientes con enfermedad tromboembólica venosa y dímero-D negativo o débilmente positivo / Clinical characteristics and presentation form in patients with venous thromboembolism and negative or weakly positive D-dimer

Introducción: El dímero-D presenta un elevado valor predictivo negativo (VPN) para el diagnóstico de enfermedad tromboembólica venosa (ETV). Sin embargo, se ha descrito ETV en presencia de valores normales de dímero-D.Pacientes y métodosEstudio observacional prospectivo en pacientes con ETV en el Hospital Gregorio Marañón entre 2001-2022 que compara las características de presentación clínica en función de los niveles de dímero-D (< 500 ng/mL vs. ≥ 500 ng/mL).ResultadosDel total de 2.582 pacientes, 333 pacientes (12,9%) presentaron dímero-D negativo o débilmente positivo. Estos eran significativamente más jóvenes (57,9 vs. 65,3 años), con menor prevalencia de comorbilidades (cardiopatía isquémica, demencia y enfermedad renal crónica), mayor historia familiar de ETV (8,4% vs. 5,2%) y trombofilia (11,7% vs. 7,8%). Presentaron significativamente menor disnea (57,6% vs. 75,4%), síncope (3% vs. 13,5%), menor carga trombótica, elevación de Nt-pro-BNP (22,0% vs. 48,2%) y dilatación del ventrículo derecho (8,1% vs. 30,0%).ConclusiónLos pacientes con ETV y niveles bajos de dímero-D al diagnóstico fueron más jóvenes, con presentación clínica más leve y menor carga trombótica; pero presentaron mayor prevalencia de trombofilia e historia familiar de ETV. (AU)

Introduction: D-dimer has a high negative predictive value for the diagnosis of venous thromboembolic disease (VTE). However, VTE has been reported in the presence of normal D-dimer values.MethodsThis is a prospective observational study in patients with VTE from Hospital Gregorio Marañón between 2001 and 2022, comparing the characteristics of clinical presentation based on D-dimer levels (<500 ng/mL vs. ≥500 ng/mL).ResultsA total of 2582 patients were found, 333 patients (12.9%) presented negative or weakly positive D-dimer levels. They were significantly younger (57.9 vs. 65.3 years), with a lower prevalence of comorbidities (ischemic heart disease, dementia, and chronic kidney disease), and a greater family history of VTE (8.4% vs. 5.2%) and thrombophilia (11.7% vs. 7.8%). They presented significantly less dyspnea (57.6% vs. 75.4%), syncope (3% vs. 13.5%), less thrombotic load, elevated NT-pro-BNP (22.0% vs. 48.2%), and right ventricle dilatation (8.1% vs. 30.0%).ConclusionPatients with VTE and low D-dimer levels at diagnosis were younger, with milder clinical presentation and lower thrombotic load; but they presented a higher prevalence of thrombophilia and a family history of VTE. (AU)

Perception of training and job perspectives among final-year residents in the specialty of Endocrinology and Nutrition.

INTRODUCTION: The medical specialisation model in Spain is carried out in the context of specialised health training, through the residency programme. The aim of the study is to analyse, by an anonymous survey, the opinion on three aspects among final-year residents in Endocrinology and Nutrition (E&N): self-assessment of the knowledge acquired, working prospects, care and training consequences arising from the pandemic COVID-19. MATERIALS AND METHODS: Cross-sectional observational study using a voluntary and anonymous online survey, shared among final-year national interns in the last year of the E&N programme, carried out between June-July 2021. RESULTS: 51 responses were obtained, 66% of the fourth-year residents. Overall perception of their knowledge was 7.8 out of 10. Most external rotations were in thyroid and nutrition areas. A total of 96.1% residents, carried out some activity associated with COVID-19, with a training deterioration of 6.9 out of 10. 88.2% cancelled their rotations and 74.5% extended their working schedule. The average negative emotional impact was 7.3 out of 10. 80.4% would like to continue in their training hospital, remaining 45.1%. 56.7% have an employment contract of less than 6 months, most of them practising Endocrinology. CONCLUSION: The perception of the knowledge acquired during the training period is a "B". Residents consider that the pandemic has led to a worsening of their training, generating a negative emotional impact. Employment outlook after completing the residency can be summarised as: temporality, practice of Endocrinology and interhospital mobility.

Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.

Melatonin is a molecule with different antitumor actions in breast cancer and has been described as an inhibitor of vascular endothelial growth factor (VEGF). Despite the recognition of the key role exerted by VEGF in tumor angiogenesis, limitations arise when developing models to test new antiangiogenic molecules. Thus, the aim of this study was to develop rapid, economic, high capacity and easy handling angiogenesis assays to test the antiangiogenic effects of melatonin and demonstrate its most effective dose to neutralize and interfere with the angiogenic sprouting effect induced by VEGF and MCF-7. To perform this, 3D endothelial cell (HUVEC) spheroids and a chicken embryo chorioallantoic membrane (CAM) assay were used. The results showed that VEGF and MCF-7 were able to stimulate the sprouting of the new vessels in 3D endothelial spheroids and the CAM assay, and that melatonin had an inhibitory effect on angiogenesis. Specifically, as the 1 mM pharmacological dose was the only effective dose able to inhibit the formation of ramifications around the alginate in the CAM assay model, this inhibition was shown to occur in a dose-dependent manner. Taken together, these techniques represent novel tools for the development of antiangiogenic molecules such as melatonin, with possible implications for the therapy of breast cancer.

[Clinical characteristics and presentation form in patients with venous thromboembolism and negative or weakly positive D-dimer]. / Características clínicas y forma de presentación en pacientes con enfermedad tromboembólica venosa y dímero-D negativo o débilmente positivo.

INTRODUCTION: D-dimer has a high negative predictive value for the diagnosis of venous thromboembolic disease (VTE). However, VTE has been reported in the presence of normal D-dimer values. METHODS: This is a prospective observational study in patients with VTE from Hospital Gregorio Marañón between 2001 and 2022, comparing the characteristics of clinical presentation based on D-dimer levels (<500 ng/mL vs. ≥500 ng/mL). RESULTS: A total of 2582 patients were found, 333 patients (12.9%) presented negative or weakly positive D-dimer levels. They were significantly younger (57.9 vs. 65.3 years), with a lower prevalence of comorbidities (ischemic heart disease, dementia, and chronic kidney disease), and a greater family history of VTE (8.4% vs. 5.2%) and thrombophilia (11.7% vs. 7.8%). They presented significantly less dyspnea (57.6% vs. 75.4%), syncope (3% vs. 13.5%), less thrombotic load, elevated NT-pro-BNP (22.0% vs. 48.2%), and right ventricle dilatation (8.1% vs. 30.0%). CONCLUSION: Patients with VTE and low D-dimer levels at diagnosis were younger, with milder clinical presentation and lower thrombotic load; but they presented a higher prevalence of thrombophilia and a family history of VTE.

Desarrollo de una solución integrada para pacientes con dolor crónico portadores de neuroestimulador en tiempos del COVID-19: una aplicación para móvil con centro de soporte / Development of an integrated solution for patients with neurostimulator for chronic pain in times of COVID-19: A mobile application with a support center

Introducción El dolor crónico es una de las afecciones más prevalentes en el mundo. El tratamiento con neuroestimuladores se realiza en los casos más extremos tras una cuidadosa selección, y demanda una gran inversión de recursos en su seguimiento. En estos momentos de pandemia por la COVID-19, presentamos una solución integrada para el seguimiento de estos de pacientes, que incluye el desarrollo de una aplicación para dispositivos móviles y un centro de soporte para seguimiento remoto (CSSR). Material y metodología El proyecto se ha desarrollado basándose en evidencia científica en las siguientes fases: 1) Aprobación de la idea en sesión clínica multidisciplinar de implantes para dolor crónico, 2) Formación de un grupo de expertos, 3) Adaptación del protocolo para el seguimiento de los pacientes con dolor crónico a las características del entorno de un smartphone, 4) Adaptación de la plataforma tecnológica al protocolo clínico (entorno tecnológico y flujo de trabajo entre el hospital y el CSSR) y 5) Evaluación de la calidad mediante encuesta (cuantitativa y cualitativa) con una pequeña muestra de pacientes. Resultados La aplicación de paciente se evaluó solicitando opiniones de los usuarios sobre el diseño y la utilidad de la misma entre los primeros pacientes implantados que la usaron. Se realizaron algunos ajustes menores en relación con el material para descargar, y sobre el texto y el color de la pantalla. Conclusiones El proceso de creación de una solución integrada debe estar basado en principios científicos y acorde con los protocolos establecidos. Un centro de soporte permite asegurar una mayor adherencia al seguimiento y una mejor atención a los pacientes (AU)

Introduction Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of COVID-19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). MMaterial and methodology The project was developed according to the scientific evidence in the following phases: (1) approval in a multidisciplinary clinical committee of implants for chronic pain, (2) setting up a group of experts, (3) protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) quality evaluation by survey (quantitative and qualitative) of a small series of patients. Results The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. Conclusions Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care (AU)

[Development of an integrated solution for patients with neurostimulator for chronic pain in times of COVID-19: A mobile application with a support center]. / Desarrollo de una solución integrada para pacientes con dolor crónico portadores de neuroestimulador en tiempos del COVID-19: una aplicación para móvil con centro de soporte.

Introduction: Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of COVID-19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). MMaterial and methodology: The project was developed according to the scientific evidence in the following phases: (1) approval in a multidisciplinary clinical committee of implants for chronic pain, (2) setting up a group of experts, (3) protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) quality evaluation by survey (quantitative and qualitative) of a small series of patients. Results: The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. Conclusions: Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care.

Actualización en el tratamiento del hipoparatiroidismo posquirúrgico / Update on management of postoperative hypoparathyroidism

Introducción y objetivo: El hipoparatiroidismo posquirúrgico es una complicación frecuente de la cirugía tiroidea y paratiroidea, con consecuencias significativas sobre la salud y calidad de vida. El objetivo de esta revisión es proporcionar una visión actualizada de su prevención, detección precoz y tratamiento.Síntesis: Tras la tiroidectomía y paratiroidectomía puede aparecer hipoparatiroidismo de forma aguda, especialmente en algunos pacientes de alto riesgo. La determinación de la hormona paratiroidea intacta (PTHi) en el postoperatorio temprano es una herramienta útil en el manejo del paciente. Un nivel de PTHi postoperatoria <10-15 pg/ml, combinado con los niveles de calcemia 24 horas después de la cirugía, ofrece el mejor valor predictivo para hipocalcemia aguda. El hipoparatiroidismo permanente se asocia con morbilidad y deterioro de calidad de vida a largo plazo y debería prevenirse cuando sea posible. El tratamiento convencional incluye calcio oral y metabolitos activos de vitamina D. En caso de hipocalcemia severa o sintomática se precisa calcio intravenoso. El tratamiento debe monitorizarse e incluir educación sanitaria del paciente, para evitar amplias desviaciones de la calcemia. Sin embargo, con la terapia convencional mantener un adecuado control puede representar un desafío. (AU)

Introduction and objective: Surgical hypoparathyroidism is a common complication following thyroid and parathyroid surgery. It has significant consequences for health and quality of life. The objective of this review is to provide an overview of its prevention, early detection, and treatment. Synthesis: Acute hypoparathyroidism can occur after thyroidectomy and parathyroidectomy, especially in high-risk patients. Measurement of early postoperative intact parathyroid hormone (PTHi) can help guide patient management. A postoperative PTHi < 10-15 pg/ml combined with serum calcium assay testing 24 hours after surgery yielded the highest diagnostic accuracy for predicting acute hypocalcemia. Permanent hypoparathyroidism is associated with long-term morbidity and poor quality of life, and should be prevented whenever possible. Conventional treatment consist of oral calcium and active vitamin D analogs. For more severe or symptomatic hypocalcemia it is necessary intravenous calcium. Treatment require monitoring and patient education to avoid wide swings in serum calcium. However, with standard therapy, maintaining an adequate control often presents a therapeutic challenge. Recombinant human parathyroid hormone (rhPTH) replacement can lower the doses of calcium and active vitamin D analogs required, while maintaining serum calcium and phosphate levels within the recommended therapeutic ranges. It may improve bone metabo-lism and quality of life on the long term. Additional data on safety and efficacy are needed. Conclusions: Postoperative hypoparathyroidism is common. It requires early diagnosis, pharmacologic intervention and patient education to achieve optimal control and lower the risk of long-term complications. rhPTH seems to be an effective option for those patients who do not stably mantein their calcium in the target range. (AU)

Inhibitory control and obesity in adolescents: A prospective cohort study.

INTRODUCTION: Inhibitory control (IC) is an executive function that plays a central role in the capability to control one's attention and behavior. Growing evidence suggests that deficits in IC are related to calorie consumption and obesity development. However, there are only a few studies that have addressed this issue prospectively. The aim of the present study was to evaluate the influence of IC on anthropometric changes at one year follow up in a cohort of Argentinian adolescents. METHODS: A prospective cohort study of 569 students (264 boys and 305 girls) aged 13.18 ± 0.36 years at initial evaluation and 14.22 ± 0.29 years at follow up was performed. IC was assessed at baseline and at follow up by means of a computerized Go/No-Go task, and anthropometric measures were performed following standardized procedures. At follow up an abbreviated Three Factor Eating Questionnaire (TFEQ-R21C) was performed. RESULTS: Cross sectional analysis performed at the age of 14 revealed an association between IC and obesity, meanwhile at the age of 13 IC was associated with the degree of obesity. Prospective analysis showed that a lower IC at baseline predicted a higher increase in body mass index (BMI) and waist circumference at one year of follow up. Subjects with lower IC at follow up rated higher in the uncontrolled eating domain of TFEQ-R21C and presented higher snacking frequency. CONCLUSIONS: A higher IC capacity at baseline might be associated with a more favorable evolution in BMI and waist circumference. A low IC at follow up is associated with obesity and higher uncontrolled eating. This suggests that the identification of subjects with low IC might be useful in order to detect adolescents at risk of obesity at earlier stages.

Development of an integrated solution for patients with neurostimulator for chronic pain in times of COVID-19: A mobile application with a support center.

INTRODUCTION: Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of the COVID19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). MATERIAL AND METHODOLOGY: The project was developed according to the scientific evidence in the following phases: (1) Approval in a multidisciplinary clinical committee of implants for chronic pain, (2) Setting up a group of experts, (3) Protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) Technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) Quality evaluation by survey (quantitative and qualitative) of a small series of patients. RESULTS: The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. CONCLUSIONS: Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care.

Spanish Translation and Linguistic Validation of the Glucose Monitoring Experiences Questionnaire (GME-Q) in Continuous Glucose Monitoring Users.

BACKGROUND AND AIMS: The use of continuous glucose monitoring (CGM) has become standard practice in people with type 1 diabetes. The evaluation of user satisfaction is crucial. The Glucose Monitoring Experiences questionnaire (GME-Q) includes 23 items with a 5-point Likert scale to produce a total satisfaction score and three subscale scores. The study aimed to translate the GME-Q from English into Spanish and to validate its use in Spanish-speaking CGM users with type 1 diabetes. METHODS: The linguistic translation and validation process of the GME-Q was established. T1D CGM users were asked to complete the produced Spanish version of the GME-Q and interviewed about difficulties or misunderstandings. Total satisfaction, effectiveness, convenience and intrusiveness subscales and internal consistency reliability were computed. RESULTS: Forward and backward translations and cognitive debriefing produced a final version of the GME-Q in Spanish. Ninety-eight subjects with type 1 diabetes were selected (age: 40 ± 12 years, 63% females, Hb1c: 7.2 ± 0.9% (55 ± 10 mmol/l), pump users: 78%, CGM use: 3.7 ± 2.6 years). The completion rate was 99% and the Cronbach's alpha coefficient was 0.8. The total satisfaction score was 3.9 ± 0.4 (effectiveness: 4.1 ± 0.6, convenience: 3.8 ± 0.6, intrusiveness: 2.2 ± 0.7). CONCLUSION: The GME-Q was translated into Spanish and validated for Spanish-speaking CGM users with type 1 diabetes.

Myocardial Geometry and Dysfunction in Morbidly Obese Adolescents (BMI 35-40 kg/m2).

This study evaluated the preclinical effect of obesity on the ventricular remodeling in adolescents with morbid obesity, and determined if subjects labelled as metabolically healthy obesity (MHO) presented better heart index than those with metabolically unhealthy obesity (MUO). Prospective case-control research of 45 adolescents (14-year-old) with morbid obesity and 25 normal weight adolescents' gender- and age-matched with Tanner stage 4-5. Left ventricle (LV) was evaluated by conventional Doppler echocardiography, tissue Doppler imaging and two-dimensional speckle tracking echocardiography. Compared to normal-weight subjects, adolescents with morbid obesity presented a high percentage of pathological LV geometry (87%; p<0.01), and systolic and diastolic dysfunctions only detected by E/A ratio (2.0 vs 1.7, p<0.01), global longitudinal strain (-21.0% vs -16.5%, p<0.01), and early diastolic strain rate (3.2 vs 2.2, p<0.01). A correlation was found between impaired cardiac index and body mass index (BMI), high blood pressure, hyperglycemia, low HDL-cholesterol and hypertriglyceridemia. BMI and HDL-cholesterol were the most significant independent variables. No significant differences were found in structural and functional cardiac index when MHO and MUO subjects were compared (global longitudinal strain: -17.0% vs -16.4%, p0.79). Morbidly obese adolescents have an abnormal LV geometry, closely related to BMI, and systolic and diastolic LV dysfunctions. Adolescents labelled as MHO, despite exhibiting better BMI and insulin-resistance values, present the same pathological heart changes as MUO.

Prevalencia de trastornos respiratorios del sueño en adolescentes y su relación con la presencia de obesidad e hipertensión arterial / Prevalence of sleep-disordered breathing among adolescents and its association with the presence of obesity and hypertension

Introducción: El aumento de prevalencia de trastornos respiratorios del sueño (TRS) y su relación con obesidad e hipertensión arterial (HTA) ha sido poco explorado en adolescentes. El objetivo de este estudio fue investigar la prevalencia de TRS y ronquido en esta población y analizar su asociación con obesidad e HTA. Población y métodos: Se realizó un estudio descriptivo de corte transversal en una muestra de adolescentes. Se realizaron mediciones de peso, talla, perímetro de cintura y cuello, tensión arterial, y el Cuestionario de Sueño Pediátrico (PSQ, por su sigla en inglés). Resultados: Participaron 826 adolescentes, 58 (7 %) presentaron TRS (varones: 5,8 %; mujeres: 8 %) y 80 (9,7 %) se consideraron roncadores (varones: 10,4 %; mujeres: 9,1 %). Se detectaron sobrepeso y obesidad en 216 (26,2 %) y 149 (18 %) sujetos, respectivamente. Una mayor proporción de sujetos con obesidad presentaron TRS con respecto a quienes no tenían obesidad (12,8 % versus 5,8 %; p = 0,004). La misma asociación fue encontrada para el ronquido (18,2 % versus 7,8 %; <0,001). El 24,6 % dormía menos de 8 horas por día. El 12,6 % presentó valores compatibles con HTA, con una asociación significativa con obesidad y horas de sueño. Conclusión: Se observó una prevalencia elevada de TRS y ronquido en adolescentes y una asociación entre obesidad e HTA, que pone de manifiesto la importancia de abordar esta problemática de manera temprana a fin de evitar complicaciones

ntroduction: The increased prevalence of sleep-disordered breathing (SDB) and its association with obesity and hypertension (HTN) have not been thoroughly explored in adolescents. The objective of this study was to investigate the prevalence of SDB and snoring in this population and analyze its association with obesity and HTN. Population and methods: This was a descriptive, cross-sectional study in a sample of adolescents. Weight, height, waist and neck circumference, and blood pressure were measured, and the Pediatric Sleep Questionnaire (PSQ) was administered. Results: A total of 826 adolescents participated, 58 (7 %) had SDB (males: 5.8 %; females: 8 %), and 80 (9.7 %) were considered snorers (males: 10.4 %; females: 9.1 %). Overweight and obesity were detected in 216 (26.2 %) and 149 (18 %) participants, respectively. A higher proportion of subjects with obesity had SDB compared to those who were not obese (12.8 % versus 5.8 %; p = 0.004). The same association was observed with snoring (18.2 % versus 7.8 %; p < 0.001). Also, 24.6 % slept less than 8 hours a day and 12.6 % had values compatible with HTN, with a significant association with obesity and sleep hours. Conclusion: A high prevalence of SDB and snoring was observed in adolescents, together with an association with obesity and HTN, which highlights the relevance of addressing this problem in an early manner in order to prevent complications

Prevalence of sleep-disordered breathing among adolescents and its association with the presence of obesity and hypertension. / Prevalencia de trastornos respiratorios del sueño en adolescentes y su relación con la presencia de obesidad e hipertensión arterial.

INTRODUCTION: The increased prevalence of sleepdisordered breathing (SDB) and its association with obesity and hypertension (HTN) have not been thoroughly explored in adolescents. The objective of this study was to investigate the prevalence of SDB and snoring in this population and analyze its association with obesity and HTN. POPULATION AND METHODS: This was a descriptive, cross-sectional study in a sample of adolescents. Weight, height, waist and neck circumference, and blood pressure were measured, and the Pediatric Sleep Questionnaire (PSQ) was administered. RESULTS: A total of 826 adolescents participated, 58 (7%) had SDB (males: 5.8%; females: 8%), and 80 (9.7%) were considered snorers (males: 10.4%; females: 9.1%). Overweight and obesity were detected in 216 (26.2%) and 149 (18%) participants, respectively. A higher proportion of subjects with obesity had SDB compared to those who were not obese (12.8% versus 5.8%; p = 0.004). The same association was observed with snoring (18.2% versus 7.8%; p < 0.001). Also, 24.6% slept less than 8 hours a day and 12.6% had values compatible with HTN, with a significant association with obesity and sleep hours. CONCLUSION: A high prevalence of SDB and snoring was observed in adolescents, together with an association with obesity and HTN, which highlights the relevance of addressing this problem in an early manner in order to prevent complications.

Introducción: El aumento de prevalencia de trastornos respiratorios del sueño (TRS) y su relación con obesidad e hipertensión arterial (HTA) ha sido poco explorado en adolescentes. El objetivo de este estudio fue investigar la prevalencia de TRS y ronquido en esta población y analizar su asociación con obesidad e HTA. Población y métodos: Se realizó un estudio descriptivo de corte transversal en una muestra de adolescentes. Se realizaron mediciones de peso, talla, perímetro de cintura y cuello, tensión arterial, y el Cuestionario de Sueño Pediátrico (PSQ, por su sigla en inglés). Resultados: Participaron 826 adolescentes, 58 (7%) presentaron TRS (varones: 5,8%; mujeres: 8%) y 80 (9,7%) se consideraron roncadores (varones: 10,4%; mujeres: 9,1%). Se detectaron sobrepeso y obesidad en 216 (26,2%) y 149 (18%) sujetos, respectivamente. Una mayor proporción de sujetos con obesidad presentaron TRS con respecto a quienes no tenían obesidad (12,8% versus 5,8%; p = 0,004). La misma asociación fue encontrada para el ronquido (18,2% versus 7,8%;<0,001). El 24,6% dormía menos de 8 horas por día. El 12,6% presentó valores compatibles con HTA, con una asociación significativa con obesidad y horas de sueño. Conclusión: Se observó una prevalencia elevada de TRS y ronquido en adolescentes y una asociación entre obesidad e HTA, que pone de manifiesto la importancia de abordar esta problemática de manera temprana a fin de evitar complicaciones.